ALC and STAA Related Headlines
Go Back- Alcon terminates merger agreement with STAAR Surgical
- Alcon Terminates Agreement to Acquire STAAR Surgical
- Exclusive: STAAR Surgical deal fails as shareholder support remains at around 30%
- Broadwood Partners Comments on STAAR Surgical Shareholders’ Rejection of Proposed Sale to Alcon
- Broadwood Partners Comments on STAAR Surgical Shareholders’ Rejection of the Company’s Proposed Sale to Alcon
- Exclusive: STAAR merger with Alcon still fails to gain traction, only 30% vote for
- Broadwood criticizes STAAR Surgical's fourth delay of shareholder vote
- Broadwood Partners Denounces STAAR Surgical’s Fourth Delay of the Shareholder Vote on the Company’s Proposed Sale to Alcon
- Alcon exercises right to adjourn STAAR Surgical stockholder meeting
- Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders
- Broadwood sees $50/share path for STAAR Surgical as merger battle nears voting day
- Defender Capital opposes STAAR Surgical sale to Alcon ahead of vote
- Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.
- Broadwood pledges cooperation with STAAR Surgical after Alcon deal vote
- Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails
- STAAR Surgical urges shareholders to approve Alcon's $30.75 per share offer
- STAAR Stockholders Have a Choice: Vote FOR Alcon’s Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value
- ISS recommends STAAR Surgical deal, but warns shareholders have reason to object
- Yunqi Capital opposes STAAR merger with Alcon despite revised offer
- Yunqi Capital Comments on Proxy Advisors’ Updated Recommendations, Urges Shareholders to Continue to Back the Company’s Standalone Trajectory
- STAAR Surgical gets analyst support for Alcon merger at $30.75 per share
- Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction
- Broadwood Partners opposes STAAR Surgical sale to Alcon amid proxy concerns
- Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon
- Leading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote “FOR” Alcon Merger
- Glass Lewis reaffirms opposition to STAAR Surgical sale to Alcon
- Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation “AGAINST” STAAR Surgical Sale to Alcon
- STAAR Surgical defends merger process amid activist criticism
- STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process
- Broadwood opposes revised STAAR Surgical-Alcon deal, cites board dissent
- Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon
- STAAR Surgical falls as Yunqi Capital reiterates opposition to merger with Alcon
- Yunqi Capital opposes STAAR Surgical merger despite Alcon's raised bid
- Yunqi Capital Comments on STAAR Surgical’s Go-Shop Process and Alcon’s Revised Offer
- Alcon bumps STAAR Surgical bid to $30.75, but Broadwood remains vehemently against
- Broadwood opposes revised STAAR Surgical acquisition by Alcon
- Broadwood Partners Responds to Alcon’s Increase to Proposed Acquisition Price of STAAR Surgical
- Alcon raises STAAR acquisition price to $30.75 per share
- Alcon Announces Amended Merger Agreement with STAAR Surgical
- Broadwood Partners maintains opposition to STAAR Surgical sale to Alcon
- Broadwood Partners Reiterates Opposition to STAAR Surgical’s Sale to Alcon Following Conclusion of Performative Go-Shop Process
- Egan-Jones reaffirms vote against STAAR Surgical sale to Alcon
- Broadwood Partners: Proxy Advisory Firm Egan-Jones Reaffirms Its Recommendation STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon
- STAAR Surgical's go-shop period expires with no competing bids
- STAAR Surgical Announces Expiration of Go-Shop Period
- Broadwood reiterates push for STAAR Surgical board shake-up as Alcon vote nears
- Broadwood Partners seeks to remove three STAAR Surgical directors
- Broadwood Partners Working to Call Special Meeting of STAAR Surgical Shareholders to Remove Three Directors
- STAAR Surgical reveals board dissent over amended Alcon deal ahead of vote
- Exclusive: Broadwood says Alcon's earnings reveal STAAR bid came from 'weakness'
- Broadwood calls for new directors at STAAR Surgical for go-shop oversight
- Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process
- STAAR Surgical amends Alcon merger deal to allow 30-day bidding period
- STAAR Surgical Announces Amendments to Alcon Merger Agreement
- Yunqi Capital urges STAAR shareholders to reject Alcon merger after Q3 results
- Yunqi Capital Applauds STAAR Surgical’s Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated
- Alcon, Broadwood trade blows in fight for STAAR Surgical's future
- Broadwood opposes Alcon's STAAR Surgical acquisition bid
- Broadwood Partners Condemns Alcon’s Fallacious Attacks on STAAR Surgical and Its Prospects
- Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders
- Yunqi Capital calls for termination of STAAR-Alcon merger deal
- Yunqi Capital Issues Letter to STAAR Surgical Board Calling for Termination of the Proposed Merger with Alcon
- Alcon rejects raised bid for STAAR Surgical as shareholders revolt
- STAAR Surgical postpones shareholder vote on Alcon merger to December
- STAAR Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon
- Yunqi Capital urges STAAR Surgical to end Alcon merger deal
- Yunqi Capital Issues Letter to STAAR Surgical Board Opposing Adjournment of the Special Meeting and Calling for the Company to Move Beyond the Proposed Merger with Alcon
- Exclusive: Roughly 72% of STAAR shares oppose Alcon deal, vote delayed
- Broadwood seeks to remove STAAR Surgical directors after vote delay
- Broadwood Partners Condemns Decision by STAAR Surgical and Alcon to Delay Final Vote on Proposed Transaction
- STAAR postpones stockholder meeting on Alcon merger to November
- Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders
- Broadwood moves to oust STAAR Surgical directors over Alcon deal
- Yunqi Capital issues new letter to STAAR Surgical (STAA) Board
- Yunqi Capital Issues Letter to STAAR Surgical’s Board Calling for Timely Convening of the Special Meeting to Vote on the Alcon Transaction
- Broadwood Partners rallies opposition to STAAR Surgical-Alcon deal
- Broadwood Partners Highlights Growing Opposition to STAAR Surgical’s Proposed Sale to Alcon
- Broadwood urges STAAR board to proceed with shareholder vote on Alcon deal
- Broadwood Partners Issues Letter to STAAR Surgical’s Board Urging it to Allow Timely Shareholder Vote on Alcon Sale
- ISS joins other advisors opposing STAAR-Alcon deal
- Broadwood Partners: All Three Leading Proxy Advisory Firms Recommend STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon
- Broadwood Partners Comments on STAAR Surgical’s Late and Troubling Disclosure in Deeply Flawed Sale Process to Alcon
- Broadwood Partners questions STAAR Surgical board over Alcon sale process
- Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Diligence in Rush to Reaffirm Support for Alcon Sale
- Glass Lewis recommends against STAAR–Alcon merger, bolstering Broadwood’s campaign
- STAAR Surgical board urges shareholders to approve Alcon merger
- STAAR Surgical Board of Directors Reiterates Unanimous Recommendation that STAAR Stockholders Vote “FOR” the Alcon Merger Agreement on WHITE Proxy Card
- Glass Lewis recommends STAAR shareholders vote against Alcon acquisition
- Broadwood Partners: Leading Advisory Firm Glass Lewis Urges STAAR Shareholders to Vote “AGAINST” Sale to Alcon
- Broadwood Partners challenges STAAR Surgical deal with Alcon
- Broadwood Partners Questions Integrity of STAAR Surgical’s Last-Minute Forecast Change and Fairness Opinion in Sale to Alcon
- Defender Capital Opposes STAAR Surgical's Proposed Sale to Alcon
- Yunqi Capital opposes STAAR Surgical merger with Alcon
- Yunqi Capital, One of STAAR Surgical Company’s Largest Shareholders, Reiterates Its Opposition to the Proposed Merger with Alcon
- Broadwood opposes STAAR Surgical sale at $28 after rejecting $58 offer
- Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Judgment in Proposed Sale to Alcon
- STAAR Surgical: Independent Industry Analysts Recognize Merits of Alcon Merger, the Value It Provides, and the Downside Risks Facing STAAR on Standalone Basis
- Broadwood Partners opposes STAAR Surgical sale to Alcon
- Broadwood Partners Publishes Presentation Detailing Opposition to STAAR Surgical’s Sale to Alcon
- Alcon's STAAR acquisition clears antitrust review milestone
- Alcon and STAAR Surgical Announce Expiration of Hart-Scott-Rodino Waiting Period for Alcon’s Acquisition of STAAR
- Broadwood files definitive proxy, STAAR reaffirms Alcon merger
- STAAR Surgical Publishes Presentation Highlighting Compelling, Certain Cash Value Offered by Alcon Merger and Meaningful Downside Risks if Alcon Merger is not Approved
- Broadwood opposes STAAR Surgical acquisition by Alcon
- Broadwood Partners Files Definitive Proxy Statement Soliciting STAAR Surgical Stockholders to Vote “AGAINST” Proposed Acquisition by Alcon
- STAAR draws no rival bids as Yunqi joins Broadwood against Alcon deal
- STAAR Surgical Announces Expiration of “Window Shop” Period; No Competing Acquisition Proposals Received
- Yunqi Capital, 5.1% Holder and One of STAAR Surgical Company’s Largest Shareholders, Announces Intention to Vote Against the Proposed Sale to Alcon
- STAAR Surgical board recommends $28 per share Alcon merger
- STAAR Surgical Board of Directors Unanimously Believes Alcon Merger Maximizes Value for STAAR Stockholders
- Broadwood files preliminary proxy to block STAAR Surgical sale; company responds
- Exclusive: Shareholder revolt threatens Alcon's takeover of STAAR Surgical
- Alcon to acquire STAAR Surgical for $1.5 billion in cash deal
- Alcon Agrees to Acquire STAAR Surgical
ALC and STAA Related Press Releases
Go Back- Alcon Terminates Agreement to Acquire STAAR Surgical
- Broadwood Partners Comments on STAAR Surgical Shareholders’ Rejection of the Company’s Proposed Sale to Alcon
- Broadwood Partners Denounces STAAR Surgical’s Fourth Delay of the Shareholder Vote on the Company’s Proposed Sale to Alcon
- Alcon Exercises Right to Require STAAR Surgical to Adjourn its Special Meeting of Stockholders
- Defender Capital Reiterates Intention to Vote AGAINST STAAR Surgical's Proposed Sale to Alcon Inc.
- Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails
- STAAR Stockholders Have a Choice: Vote FOR Alcon’s Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value
- Yunqi Capital Comments on Proxy Advisors’ Updated Recommendations, Urges Shareholders to Continue to Back the Company’s Standalone Trajectory
- Independent Industry Analysts Recognize Value Provided to STAAR Stockholders by Amended Alcon Merger Agreement and Merits of Alcon Transaction
- Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon
- Leading Independent Proxy Advisory Firm ISS Recommends STAAR Stockholders Vote “FOR” Alcon Merger
- Broadwood Partners: Leading Proxy Advisory Firm Glass Lewis Reaffirms Recommendation “AGAINST” STAAR Surgical Sale to Alcon
- STAAR Surgical Sets the Record Straight Regarding its Robust Go-Shop Process
- Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revised Sale to Alcon
- Yunqi Capital Comments on STAAR Surgical’s Go-Shop Process and Alcon’s Revised Offer
- Broadwood Partners Responds to Alcon’s Increase to Proposed Acquisition Price of STAAR Surgical
- Alcon Announces Amended Merger Agreement with STAAR Surgical
- Broadwood Partners Reiterates Opposition to STAAR Surgical’s Sale to Alcon Following Conclusion of Performative Go-Shop Process
- Broadwood Partners: Proxy Advisory Firm Egan-Jones Reaffirms Its Recommendation STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon
- STAAR Surgical Announces Expiration of Go-Shop Period
- Broadwood Partners Working to Call Special Meeting of STAAR Surgical Shareholders to Remove Three Directors
- Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process
- STAAR Surgical Announces Amendments to Alcon Merger Agreement
- Yunqi Capital Applauds STAAR Surgical’s Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated
- Broadwood Partners Condemns Alcon’s Fallacious Attacks on STAAR Surgical and Its Prospects
- Alcon Releases Investor Discussion Materials Reinforcing Certain Value of Merger Proposal for STAAR Stockholders
- Yunqi Capital Issues Letter to STAAR Surgical Board Calling for Termination of the Proposed Merger with Alcon
- STAAR Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon
- Yunqi Capital Issues Letter to STAAR Surgical Board Opposing Adjournment of the Special Meeting and Calling for the Company to Move Beyond the Proposed Merger with Alcon
- Broadwood Partners Condemns Decision by STAAR Surgical and Alcon to Delay Final Vote on Proposed Transaction
- Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders
- Yunqi Capital Issues Letter to STAAR Surgical’s Board Calling for Timely Convening of the Special Meeting to Vote on the Alcon Transaction
- Broadwood Partners Highlights Growing Opposition to STAAR Surgical’s Proposed Sale to Alcon
- Broadwood Partners Issues Letter to STAAR Surgical’s Board Urging it to Allow Timely Shareholder Vote on Alcon Sale
- Broadwood Partners: All Three Leading Proxy Advisory Firms Recommend STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon
- Broadwood Partners Comments on STAAR Surgical’s Late and Troubling Disclosure in Deeply Flawed Sale Process to Alcon
- Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Diligence in Rush to Reaffirm Support for Alcon Sale
- STAAR Surgical Board of Directors Reiterates Unanimous Recommendation that STAAR Stockholders Vote “FOR” the Alcon Merger Agreement on WHITE Proxy Card
- Broadwood Partners: Leading Advisory Firm Glass Lewis Urges STAAR Shareholders to Vote “AGAINST” Sale to Alcon
- Broadwood Partners Questions Integrity of STAAR Surgical’s Last-Minute Forecast Change and Fairness Opinion in Sale to Alcon
- Defender Capital Opposes STAAR Surgical's Proposed Sale to Alcon
- Yunqi Capital, One of STAAR Surgical Company’s Largest Shareholders, Reiterates Its Opposition to the Proposed Merger with Alcon
- Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Judgment in Proposed Sale to Alcon
- STAAR Surgical: Independent Industry Analysts Recognize Merits of Alcon Merger, the Value It Provides, and the Downside Risks Facing STAAR on Standalone Basis
- Broadwood Partners Publishes Presentation Detailing Opposition to STAAR Surgical’s Sale to Alcon
- Alcon and STAAR Surgical Announce Expiration of Hart-Scott-Rodino Waiting Period for Alcon’s Acquisition of STAAR
- STAAR Surgical Publishes Presentation Highlighting Compelling, Certain Cash Value Offered by Alcon Merger and Meaningful Downside Risks if Alcon Merger is not Approved
- Broadwood Partners Files Definitive Proxy Statement Soliciting STAAR Surgical Stockholders to Vote “AGAINST” Proposed Acquisition by Alcon
- STAAR Surgical Announces Expiration of “Window Shop” Period; No Competing Acquisition Proposals Received
- Yunqi Capital, 5.1% Holder and One of STAAR Surgical Company’s Largest Shareholders, Announces Intention to Vote Against the Proposed Sale to Alcon
- STAAR Surgical Board of Directors Unanimously Believes Alcon Merger Maximizes Value for STAAR Stockholders
- Alcon Agrees to Acquire STAAR Surgical
